ArticleResearch square2025
Assessment of a new class of slow γ-aminobutyric acid type A receptor anesthetic on mouse neuronal and astrocyte mitochondrial function.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Our previous work has demonstrated efficacy of a new chemical class of the slow γ-aminobutyric acid type A receptor anesthetics that produce minimal effects on breathing and hemodynamics in rats. To advance pre-clinical testing, we screened one member of our class of compounds, KSEB 14 - 01, for mitochondrial toxicity in primary neuronal and astrocyte cultures from mice. Prior to treatment, cell cultures were incubated with: Mitotracker GreenTM to assess mitochondrial density, tetramethylrhodamine ethyl ester to assess mitochondrial membrane potential, dihydroethidium to assess reactive oxygen species (ROS), and 4',6-diamidino-2-phenylindole for cell counting. Cultures were treated with either propofol or KSEB 14 - 01 (dissolved in dimethylsulfoxide) at concentrations of 5, 10, or 30μM. ROS and mitochondrial membrane potential were measured for 6h after which mitochondrial density and cell proliferation were quantified. In parallel experiments, continuous oxygen consumption rates (OCR) were measured during glucose deprivation (GD) in astrocyte cultures. No significant differences were observed in cell count or between treatments. In both neurons and astrocytes, mitochondrial membrane potential was decreased at 6h with 5μM propofol and KSEB 14 - 01 treatment, but remained stable with higher doses of propofol and KSEB 14 - 01. Neuronal ROS generation increased in all groups by 6h but was significantly lower with 10 and 30μM propofol and KSEB 14 - 01. In all treatment groups, astrocyte ROS generation was significantly increased after 6h, with no differences between groups. After 48h GD astrocyte OCR was maintained with all doses of KSEB 14 - 01 and with the highest dose of propofol. In conclusion, this study demonstrates that KSEB 14 - 01 does not exhibit any overt mitochondrial toxicity relative to propofol in either neurons or astrocytes. Future in vivo work is warranted to explore the mechanisms and applications for maintenance of bioenergetic equivalents during cell stress with KSEB 14 - 01.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.